ReShape Lifesciences Price To Sales Ratio Over Time
| RSLS Stock | USD 5.55 0.03 0.54% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ReShape Lifesciences Performance and ReShape Lifesciences Correlation. ReShape |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 76.2 | Revenue Per Share 27.638 | Quarterly Revenue Growth (0.13) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price To Sales Ratio Analysis
Compare ReShape Lifesciences and related stocks such as SINTX Technologies, Bone Biologics Corp, and RA Medical Systems Price To Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SINT | 632 | 632 | 555 | 574 | 182 | 153 | 153 | 174 | 4.1 K | 673 | 8.7 K | 4.4 K | 972 | 11.1505 | 10.59 |
| BBLG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TIVC | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 28.4202 | 13.8995 | 11.624 | 3.3645 | 1.2138 | 1.15 |
| NUWE | 1.5 B | 2.1 K | 2.1 K | 2.1 K | 243 | 415 | 5.3279 | 0.6479 | 0.5527 | 0.3802 | 1.5446 | 0.9931 | 0.2183 | 0.1287 | 0.12 |
| TNON | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 37.7 K | 46.2 K | 12.7 K | 146 | 0.9789 | 0.93 |
| HSDT | 437 | 437 | 437 | 437 | 437 | 437 | 437 | 437 | 437 | 17.0862 | 23.9097 | 24.4263 | 5.2651 | 7.5892 | 7.21 |
| HSCS | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 87.7732 | 220 | 393 | 1.3 K | 175 | 349 |
| NURO | 0.2563 | 3.7064 | 5.8329 | 26.3093 | 23.0703 | 8.7822 | 3.2952 | 1.3777 | 2.8547 | 4.4075 | 12.9774 | 12.4825 | 1.2868 | 0.6356 | 0.6 |
| IINN | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.9767) | (2.68) | (2.81) |
ReShape Lifesciences and related stocks such as SINTX Technologies, Bone Biologics Corp, and RA Medical Systems Price To Sales Ratio description
Price to Sales Ratio is figured by comparing ReShape Lifesciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ReShape Lifesciences sales, a figure that is much harder to manipulate than other ReShape Lifesciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.My Equities
My Current Equities and Potential Positions
| ReShape Lifesciences | RSLS |
Specialization | Health Care, Health Care Equipment & Services |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 5.55
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.